The opportunities for Danish companies in China are great – and the market is more accessible than ever

Can we sell our solution in China? Danish Life Science Cluster and The Ministry of Foreign Affairs of Denmark have established a new partnership to make it more accessible for Danish medtech and life science companies to access the Chinese market. Look here and get an answer to whether your next export adventure should take place in China.

7. February 2023 | Christina Prangsgaard Carstensen, cpc@danishlifesciencecluster.dk

It needs to be more manageable for Danish companies that specialise in medtech, healthtech and rehabilitation to attain commercial experience on the Chinese hospital market – and, in the long run, become Danish export adventures.

Danish Life Science Cluster, The Ministry of Foreign Affairs of Denmark, and Nordic Life Science Platform ApS have formed a partnership to make access to a rapidly growing Chinese hospital market more transparent.

– The opportunities in China are great. The complexity and access barriers to establishing commercial experience in the Chinese hospital market have significantly reduced. This makes China an exciting potential market for Danish companies, says Marco Thomas Lund, internationalisation advisor at the Ministry of Foreign Affairs and Danish Life Science Cluster.

Get a step-by-step model for China.

Several Danish Life Science Cluster members have participated in the webinar: Get fast-track market access to a rapidly growing Chinese healthcare market.

Watch or re-watch the webinar and be introduced to the Chinese market and get a step-by-step model for market access via the preferential zone Hainan Boao Lecheng International Medical Zone.

Danish companies can use the partnership between the Danish Life Science Cluster, The Ministry of Foreign Affairs of Denmark, and the Nordic Life Science Platform to:

  • Get help clarifying the potential for solutions.
  • Factual matchmaking with private Chinese hospitals and clinics
  • Advice and utilisation during the fast-track approval procedures that leads to the first commercial experiences in China.

Furthermore, other interested companies and Danish Life Science Cluster are currently collecting data essential to obtain the regulatory approvals to import and commercialise company’s solution in the rest of China.

If you want to learn more about the opportunities for your company through the partnership, contact Marco Thomas Lund.

Current news